Key Features

Fmoc Protection：Optimized for solid-phase peptide synthesis (SPPS), enabling orthogonal deprotection with piperidine.

Aib Residue：Enhances peptide backbone rigidity, improving bolic stability in long-acting peptides.

Isoleucine Incorporation：Introduces hydrophobicity for improved receptor binding in GLP-1 analogs.

Applications

GLP-1 Agonist Development：Critical for constructing hydrophobic domains in long-acting peptides (e.g., Semaglutide analogs), extending half-life by 30%.

bolic Disease Research：Suitable for synthesizing peptides targeting obesity, type 2 diabetes, and non-alcoholic fatty liver disease.

Peptide Drug Formulation：Aib-induced rigidity reduces aggregation, improving formulation stability for injectable therapeutics.

Manufacturing Standards

GMP-Compliant Facility：Produced in an ISO 9001:2015 certified plant with 100% batch QC.

Global Regulatory Support：Provides DMF, CE, and REACH documentation for EU/US markets.

Stability Testing：Validated for 24 months under -20°C.

Analytical Data

2171139-20-9 HNMR

2171139-20-9 LCMS

Services Offered

Custom Modifications：Alternative protection groups (e.g., Boc, Cbz) or isotopic labeling (¹³C, ¹⁵N) for PK studies.

Scalable Production：100 mg to 10 kg batches, supporting from R&D to commercial manufacturing.

Technical Consultation：Free peptide design support by our PhD-level chemistry team.

Company Profile

15+ Years Experience：Specialized in peptide intermediates for global pharma and biotech industries.

R&D Capability：30+ scientists in a 2,000㎡ state-of-the-art laboratory.

Global Footprint：Served 500+ clients in 30+ countries, including top 10 global pharma companies.

Contact Us

Email：export@pu-kang.com

Phone：+86-137-0808-4407

Address：Zone 1 and 2, 1-3F, Building 3, Chengdu Cross-Strait Science and Technology Industrial Development Park [Jindi Weixin Wenjiang Intelligent Park], Wenjiang District, Chengdu, China.